Incidence of cancer in Finnish families with clinically aggressive and nonaggressive prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 3049-3056

  Pakkanen, Sanna ^a   Pukkala, Eero ^c,d   Kainulainen, Heidi ^c   Matikainen, Mika P ^b   Koivisto, Pasi A ^b   Tammela, Teuvo L J ^b   Schleutker, Johanna ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLON CANCER; CONNECTIVE TISSUE TUMOR; CONTROLLED STUDY; DUODENUM CANCER; ESOPHAGUS CANCER; FAMILIAL CANCER; FEMALE; FINLAND; FOLLOW UP; GALLBLADDER CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIP CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NERVOUS SYSTEM TUMOR; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RELATIVE; SMALL INTESTINE CANCER; STANDARDIZED INCIDENCE RATIO; STOMACH CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VULVA CANCER;

ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FINLAND; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC SYNDROMES, HEREDITARY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 73049115314     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0382     Document Type: Article

References (56)

1. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-1887
2. Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Lovati G. Clinicostatistical and genetic research on neoplasms of the prostate. Acta Genet Stat Med 1956-1957;6:304-305
3. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802. (Pubitemid 23241269)
4. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994;2;86:1600-1608
5. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13Spec No 1:R103-21.
6. Tavtigian SV, Simard J, Teng DHF, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-180 (Pubitemid 32157444)
7. Carpten J, Nupponen N, Isaacs S, et al. Germline muations in the ribonuklesase L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-184 (Pubitemid 34887712)
8. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-325
9. Rökman A, Ikonen T, Mononen N, et al. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001; 61:6038-6041 (Pubitemid 32762535)
10. Rökman A, Ikonen T, Seppälä EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70:1299-1304
11. Seppälä EH, Ikonen T, Autio V, et al. Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 2003;9:5252-5256 (Pubitemid 37413576)
12. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40:316-321 (Pubitemid 351311772)
13. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281-283 (Pubitemid 351311771)
14. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40:310-315 (Pubitemid 351311773)
15. Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995;87:991-996
16. Albright LA, Schwab A, Camp NJ, Farnham JS, Thomas A. Population-based risk assessment for other cancers in relatives of hereditary prostate cancer (HPC) cases. Prostate 2005;64:347-355 (Pubitemid 41193247)
17. Grönberg H, Bergh A, Damber JE, Emanuelsson M. Cancer risk in families with hereditary prostate cancer. Cancer 2000;89:1315-1321
18. Matikainen MP, Pukkala E, Schleutker J, et al. Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes Control 2001;12:223-230 (Pubitemid 32515369)
19. Eldon BJ, Jonsson E, Tomasson J, Tryggvadottir L, Tulinius H. Familial risk of prostate cancer in Iceland. BJU Int 2003;92:915-919 (Pubitemid 37548265)
20. Verhage BA, Aben KK,Witjes JA, Straatman H, Schalken JA, Kiemeney LA. Site-specific familial aggregation of prostate cancer. Int J Cancer 2004;109:611-617 (Pubitemid 38339653)
21. Negri E, Pelucchi C, Talamini R, et al. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer 2005;114:648-652 (Pubitemid 40349626)
22. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004;1:e65.
23. Hemminki K, Chen B. Familial association of prostate cancer with other cancers in the Swedish family-cancer database. Prostate 2005; 65:188-194 (Pubitemid 41362286)
24. Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758-761 (Pubitemid 27451978)
25. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-128 (Pubitemid 27323331)
26. Lorenzo Bermejo J, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 2004;15:1834-1841 (Pubitemid 40012250)
27. Stanford JL, McDonnell SK, Friedrichsen DM, et al. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 2006;66:317-325
28. Gillanders EM, Xu J, Chang BL, et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004;96: 1240-1247 (Pubitemid 39232715)
29. Christensen GB, Cannon-Albright LA, Thomas A, Camp NJ. Extracting disease risk profiles from expression data for linkage analysis: application to prostate cancer. BMC Proc 2007;1 Suppl 1:S82.
30. De la Chapelle A. Disease gene mapping in isolated human populations: the example of Finland. J Med Genet 1993;30:857-865. (Pubitemid 23299927)
31. Matikainen MP, Schleutker J, Morsky P, Kallioniemi OP, Tammela TL. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999;5:1275-1279 (Pubitemid 29282929)
32. Ikonen T, Matikainen M, Mononen N, et al. Association of E-cadherin germ-line alterations with prostate cancer. Clin Cancer Res 2001;7: 3465-3471 (Pubitemid 33069982)
33. Ikonen T, Matikainen MP, Syrjäkoski K, et al. BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. J Med Genet 2003;40:e98.
34. Seppälä EH, Ikonen T, Mononen N, et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003;89:1966-1970 (Pubitemid 37533278)
35. Fredriksson H, Ikonen T, Autio V, et al. Identification of germlineMLH1 alterations in familial prostate cancer. Eur J Cancer 2006;42:2802-2806 (Pubitemid 44739985)
36. Hebbring SJ, Fredriksson H, White KA, et al. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:935-938 (Pubitemid 43823520)
37. Lehtonen R, Kiuru M, Rökman A, et al. No fumarate hydratase (FH) mutations in hereditary prostate cancer. J Med Genet 2003;40:e19.
38. Schaid DJ, McDonnell SK, Zarfas KE, et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. 2006;120:471-485
39. Christensen GB, Camp NJ, Farnham JM, Cannon-Albright LA. Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees. The Prostate 2007;67:605-613.
40. Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevalinna H. Relationship of patients' age to histopathological features of brest tumours in BRCA1 and BRCA2 and mutation-negative brest cancer families. Breast Cancer Res 2005;7:465-469
41. Valerie A, Fournier G, Morin V, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer 2000;86:883-887 (Pubitemid 30350207)
42. Hemminki K, Dong C. Familial prostate cancer from the family-cancer database. Eur J Cancer 2000;36:229-234 (Pubitemid 30102200)
43. Jonsson BA, Bergh A, Stattin P, Emmanuelsson M, Grönberg H. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002;98: 838-843 (Pubitemid 34286678)
44. Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ. Characteristics of patients with familial versus sporadic prostate cancer. J Urol 2006; 176:2438-2442 (Pubitemid 44755061)
45. Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 1974;34:1102-1107
46. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 1992;305:855-857
47. Baffoe-Bonnie AB, Kiemeney LA, Beaty TH, et al. Segregation analysis of 389 Icelandic pedigrees with breast and prostate cancer. Genet Epidemiol 2002;23:349-363
48. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1-12. (Pubitemid 36056838)
49. Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 1993; 52:711-717 (Pubitemid 23310137)
50. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997;60:1079-1084 (Pubitemid 27194092)
51. The breast cancer linkage consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316 (Pubitemid 29387573)
52. Eerola H, Pukkala E, Pyrhonen S, Blomqvist C, Sankila R, Nevanlinna H. Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland). Cancer Causes Control 2001;12: 739-746 (Pubitemid 32803500)
53. Agalliu I, Kwon EM, Zadory D, et al. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 2007;13:839-843 (Pubitemid 46340357)
54. Sellers TA, Potter JD, Rich SS, et al. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994;86:1860-1865
55. Tung KH, Goodman MT, Wu AH, et al. Aggregation of ovarian cancer with breast, ovarian, colorectal, and prostate cancer in first-degree relatives. Am J Epidemiol 2004;159:750-758 (Pubitemid 38656132)
56. Pukkala E, Weiderpass E. Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971-1995. Int J Cancer 2002;102:643-648